
Loading, please wait...

Loading, please wait...

Researchers have developed innovative nonsymmetrical near-infrared (NIR) rhodamine-based fluorophores to improve tumor imaging and PDT. These new compounds feature large Stokes shifts and tunable emission wavelengths. Consequently, they overcome the optical limitations of traditional fluorophores in biomedical applications.
The team engineered these fluorophores by introducing varying phenothiazine moieties as auxochromes. Specifically, rhodamine incorporated with phenoselenazine shows significantly red-shifted profiles and high reactive oxygen species production. Furthermore, they created a new activatable probe for carboxylesterase (CE) by caging a secondary amine group. This probe remains in a predominantly spirolactone state until CE-catalyzed hydrolysis triggers its transition to an open zwitterion form. Therefore, clinicians can achieve highly specific imaging of enzyme activity and induce apoptosis in CE-positive cells.
Moreover, the study highlights a PEG-modified version of the probe for systemic administration. This refined probe allows for the specific imaging and ablation of tumors in living models. Since the probe targets specific enzyme activity, it significantly reduces potential off-target effects. Thus, these nonsymmetrical NIR rhodamine-based fluorophores offer a promising platform for advanced theranostic interventions in modern oncology.
Carboxylesterase is often overexpressed in various tumor types. Consequently, using it as a biological trigger ensures that the imaging signal and therapeutic effects activate only within the cancer microenvironment.
NIR wavelengths provide deeper tissue penetration and lower background interference from natural tissue fluorescence. Therefore, they are ideal for high-resolution imaging and effective photodynamic treatment of deep-seated tumors.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Zhou S et al. Nonsymmetrical Near-Infrared Rhodamines for Carboxylesterase-Activatable Tumor Imaging and Photodynamic Therapy. Anal Chem. 2026 Mar 17. doi: 10.1021/acs.analchem.5c06782. PMID: 41844510.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New NIR rhodamine fluorophores improve tumor imaging and photodynamic therapy by targeting carboxylesterase activity, enabling precise cancer cell ablation....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today